About US
Contact us
-
Study: No reason teens can't buy emergency contraception OTCGirls younger than 17 can safely use emergency contraception without a prescription, and there is no reason they can't buy it over-the-counter. At least that's the conclusion from a study whose final2012/3/23
-
GSK to build new U.K. site, create up to 1,000 jobsGood news for the U.K. coming from GlaxoSmithKline ($GSK)today. The pharma giant said it will build a new facility in Ulverston, Cumbria--its first new U.K. facility in about 40 years--to boost produc2012/3/23
-
Pharma sales execs: Current model is broken; changes are comingPharma sales and marketing execs are pessimistic about the way things are being done. In fact, a recent Booz & Company and National Analysts Worldwidesurvey found 68% of these execs believe the cu2012/3/22
-
FDA panel backs GSK's Votrient for soft-tissue sarcomaGood news came for GlaxoSmithKline ($GSK) Tuesday after the FDA's Oncologic Drugs Advisory Committee voted 11-2 in favor of approving Votrient to treatpatients with advanced soft-tissue sarcoma who ha2012/3/22
-
Bayer, others fined $15.9M by Romanian competition authorityThe Romanian Competition Council has wrapped up an ongoing investigation into alleged antitrust practices by Bayer ($BAY), Sintofarmand 9 distributors. The result: a combined €12 million in fines the2012/3/21
-
Indian government defends country's generics industryA major government official in India is blasting what he says are attempts to target the country's generic drug industry as substandard or inferior. As reported in The Economic Times,he's also seeking2012/3/21
-
Roche exec expects 'limited' rebound for pharmaDon't look for a fabulous rebound in drug sales once the patent cliff is past. So says Roche COO Pascal Soriot, who expects a paltry 2% to 3% growth in the U.S. market and stagnant sales in Europe ove2012/3/20
-
GSK to eavesdrop on social-media chatter with IT dealGlaxoSmithKline ($GSK) wants to know what consumers are saying about it online so that it can do a better job with its digital marketing. So, the London-based drug giant has inked a multimillion-dolla2012/3/20
-
Novartis persuades NICE to endorse GilenyaThe U.K.'s cost-effectiveness watchdog has changed its mind about Gilenya. The National Institute for Health and Clinical Excellence at first rejected the Novartis ($NVS) multiple sclerosis pill, in s2012/3/19
-
Can European pharma's cash flow cover buyback plans?It's no secret Big Pharma is all about dividends and stock buybacks right now. With short-term earnings under pressure from patent expirations, drugmakers have been using these promises to keep invest2012/3/19